Találati lista | Tudóstér

001-es BibID:	BIBFORM101421
035-os BibID:	(cikkazonosító)4284 (scopus)85128130388 (wos)000785465100001
Első szerző:	Buglyó Gergely (genetikus)
Cím:	Liquid Biopsy as a Source of Nucleic Acid Biomarkers in the Diagnosis and Management of Lynch Syndrome / Gergely Buglyó, Jakub Styk, Ondrej Pös, Ádám Csók, Vanda Repiska, Beáta Soltész, Tomas Szemes, Bálint Nagy
Dátum:	2022
ISSN:	1661-6596 1422-0067
Megjegyzések:	Lynch syndrome (LS) is an autosomal dominant inherited cancer predisposition disorder, which may manifest as colorectal cancer (CRC), endometrial cancer (EC) or other malignancies of the gastrointestinal and genitourinary tract as well as the skin and brain. Its genetic cause is a defect in one of the four key DNA mismatch repair (MMR) loci. Testing of patients at risk is currently based on the absence of MMR protein staining and detection of mutations in cancer tissue and the germline, microsatellite instability (MSI) and the hypermethylated state of the MLH1 promoter. If LS is shown to have caused CRC, lifetime follow-up with regular screening (most importantly, colonoscopy) is required. In recent years, DNA and RNA markers extracted from liquid biopsies have found some use in the clinical diagnosis of LS. They have the potential to greatly enhance the efficiency of the follow-up process by making it minimally invasive, reproducible, and time effective. Here, we review markers reported in the literature and their current clinical applications, and we comment on possible future directions.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Lynch syndrome colorectal cancer screening liquid biopsy circulating nucleic acids biomarker
Megjelenés:	International Journal Of Molecular Sciences. - 23 : 8 (2022), p. 4284. -
További szerzők:	Styk, Jakub Pös, Ondrej (1990-) (biológus) Csók Ádám (1994-) (biológus) Repiska Vanda Soltész Beáta (1987-) (molekuláris biológus) Szemes, Tomas (1980-) (biológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM112946
035-os BibID:	(cikkazonosító)10520 (WoS)001030973400001 (Scopus)85164844125
Első szerző:	Pös, Ondrej (biológus)
Cím:	Cross-Kingdom Interaction of miRNAs and Gut Microbiota with Non-Invasive Diagnostic and Therapeutic Implications in Colorectal Cancer / Pös Ondrej, Styk Jakub, Buglyó Gergely, Zeman Michal, Lukyova Lydia, Bernatova Kamila, Hrckova Turnova Evelina, Rendek Tomas, Csók Ádám, Repiska Vanda, Nagy Bálint, Szemes Tomas
Dátum:	2023
ISSN:	1422-0067
Megjegyzések:	Colorectal cancer (CRC) has one of the highest incidences among all types of malignant diseases, affecting millions of people worldwide. It shows slow progression, making it preventable. However, this is not the case due to shortcomings in its diagnostic and management procedure and a lack of effective non-invasive biomarkers for screening. Here, we discuss CRC-associated microRNAs (miRNAs) and gut microbial species with potential as CRC diagnostic and therapy biomarkers. We provide rich evidence of cross-kingdom miRNA-mediated interactions between the host and gut microbiome. miRNAs have emerged with the ability to shape the composition and dynamics of gut microbiota. Intestinal microbes can uptake miRNAs, which in turn influence microbial growth and provide the ability to regulate the abundance of various microbial species. In the context of CRC, targeting miRNAs could aid in manipulating the balance of the microbiota. Our findings suggest the need for correlation analysis between the composition of the gut microbiome and the miRNA expression profile.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk colorectal cancer biomarker gut microbiota microRNA
Megjelenés:	International Journal Of Molecular Sciences. - 24 : 13 (2023), p. 1-21. -
További szerzők:	Styk, Jakub Buglyó Gergely (1980-) (genetikus) Zeman, Michal Lukyova, Lydia Bernatova, Kamila Hrckova Turnova, Evelina Rendek, Tomas Csók Ádám (1994-) (biológus) Repiska Vanda Nagy Bálint (1956-) (molekuláris genetikus) Szemes, Tomas (1980-) (biológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM107654
035-os BibID:	(Scopus)85146857319 (WoS)000920608400001
Első szerző:	Styk, Jakub
Cím:	Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine : status quo and outlook / Styk Jakub, Pös Zuzana, Pös Ondrej, Radvanszky Jan, Turnova Evelina Hrckova, Buglyó Gergely, Klimova Daniela, Budis Jaroslav, Repiska Vanda, Nagy Bálint, Szemes Tomas
Dátum:	2023
ISSN:	1878-5077 1878-5085
Megjegyzések:	A form of genomic alteration called microsatellite instability (MSI) occurs in a class of tandem repeats (TRs) called microsatellites (MSs) or short tandem repeats (STRs) due to the failure of a post-replicative DNA mismatch repair (MMR) system. Traditionally, the strategies for determining MSI events have been low-throughput procedures that typically require assessment of tumours as well as healthy samples. On the other hand, recent large-scale pan-tumour studies have consistently highlighted the potential of massively parallel sequencing (MPS) on the MSI scale. As a result of recent innovations, minimally invasive methods show a high potential to be integrated into the clinical routine and delivery of adapted medical care to all patients. Along with advances in sequencing technologies and their ever-increasing cost-effectiveness, they may bring about a new era of Predictive, Preventive and Personalised Medicine (3PM). In this paper, we offered a comprehensive analysis of high-throughput strategies and computational tools for the calling and assessment of MSI events, including whole-genome, whole-exome and targeted sequencing approaches. We also discussed in detail the detection of MSI status by current MPS blood-based methods and we hypothesised how they may contribute to the shift from conventional medicine to predictive diagnosis, targeted prevention and personalised medical services. Increasing the efficacy of patient stratification based on MSI status is crucial for tailored decision-making. Contextually, this paper highlights drawbacks both at the technical level and those embedded deeper in cellular/molecular processes and future applications in routine clinical testing.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Microsatellite instability Cancer Screening Massively parallel sequencing Liquid biopsy Patient stratification Predictive Preventive Personalised Medicine (PPPM / 3PM)
Megjelenés:	EPMA Journal. - 14 : 1 (2023), p. 143-165. -
További szerzők:	Pös, Zuzana Pös, Ondrej (1990-) (biológus) Radvanszky, Jan Turnova, Evelina Hrckova Buglyó Gergely (1980-) (genetikus) Klimova, Daniela Budis, Jaroslav Repiska Vanda Nagy Bálint (1956-) (molekuláris genetikus) Szemes, Tomas (1980-) (biológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: